Farydak (Panobinostat): First HDAC Inhibitor Approved for the Treatment of Patients with Relapsed Multiple Myeloma
IMBRUVICA™ Approved For Previously Treated Chronic Lymphocytic Leukemia; Immediately Available Through Onco360®
Mekinist™ (trametinib) & Tafinlar® (dabrafenib) Approved In Combination; Both Limited Distribution Products Immediately Available Via Onco360®
Major depressive disorder (MDD) is a common, chronic medical illness that affects 5% to 8% of adults in the United States annually, which amounts to approximately 25 million people.1 Although MDD is treatable in most people, only 50% of patients with MDD ever receive treatment.1,2
Injectafer (Ferric Carboxymaltose Injection) Receives FDA Approval for the Treatment of Iron-Deficiency Anemia
Iron-deficiency anemia is the most common form of anemia.1 Iron plays a key role in producing hemoglobin (Hb) in red blood cells, which enables red blood cells to carry oxygen effectively to the body’s tissues.1,2 Anemia resulting from iron deficiency can cause tiredness, weakness, and shortness of breath.2 If left untreated, iron-deficiency anemia can become severe and can lead to heart problems, including a rapid or irregular heartbeat, which can subsequently lead to an enlarged heart or heart failure.2
PharMerica and Onco360 Finalize Strategic Investment; Establish First National Oncology Pharmacy and Care Management Platform
leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States, and Onco360, the largest independent provider of oncology pharmacy services in the United States, today announced that the companies have entered into a definitive agreement under which PharMerica has acquired a significant minority stake of Onco360.
Fetzima Extended-Release Receives FDA Approval for the Treatment of Major Depressive Disorder in Adults
Major depressive disorder (MDD), also known as clinical depression, is a chronic medical illness characterized by persistent sadness, loss of interest in normal activities, and in some cases, by physical symptoms. MDD is associated with serious emotional and biological manifestations that affect a person’s thoughts, feelings, behavior, mood, and physical health.
Simponi Aria: A New Intravenous TNF Inhibitor for the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
Rheumatoid arthritis (RA), a chronic inflammatory autoimmune disorder that affects the lining, or synovium, of the joints, affects 1.3 million people in the United States. In addition to causing painful swelling that may eventually lead to bone erosion and joint deformity, RA can also affect other organs of the body, including the skin, eyes, lungs, and blood vessels.
Breo Ellipta: A Fixed-Dose Combination Oral Inhaler Receives FDA Approval for Long-Term Maintenance Treatment of COPD
Chronic obstructive pulmonary disease (COPD) is a common, life-threatening disease characterized by a persistent blockage of airflow from the lungs. COPD encompasses a range of chronic obstructive lung diseases, including chronic bronchitis and emphysema.
Page 7 of 18
Results 61 - 70 of 172
Results 61 - 70 of 172